<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Ophthalmology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0301-4738</issn>
      <issn pub-type="epub">1998-3689</issn>
      <publisher>
        <publisher-name>Medknow Publications</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18974527</article-id>
      <article-id pub-id-type="pmc">2612971</article-id>
      <article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_6_511_43379</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Optical coherence tomography in a
patient with chloroquine-induced
maculopathy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Korah</surname>
            <given-names>Sanita</given-names>
          </name>
          <degrees>MS, DNB</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kuriakose</surname>
            <given-names>Thomas</given-names>
          </name>
          <degrees>DNB, FRCS</degrees>
        </contrib>
      </contrib-group>
      <aff>Department of Ophthalmology, Christian Medical College, Vellore,
India</aff>
      <author-notes>
        <corresp id="cor1">Correspondence to Dr. Sanita Korah, Department of Ophthalmology,
Christian Medical College, Arni Road, Vellore - 632 001, India. Email:<email>sanviji@cmcvellore.ac.in</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2008</year>
      </pub-date>
      <volume>56</volume>
      <issue>6</issue>
      <fpage>511</fpage>
      <lpage>513</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>10</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>2</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Ophthalmology</copyright-statement>
        <copyright-year>2008</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0
Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We herein report the optical coherence tomography (OCT)
findings in a case of chloroquine-induced macular toxicity,
which to our knowledge, has so far not been reported. A 53-
year-old lady on chloroquine for treatment of rheumatoid
arthritis developed decrease in vision 36 months after initiation
of the treatment. Clinical examination revealed evidence of
retinal pigment epithelial (RPE) disturbances. Humphrey
field analyzer (HFA), fundus fluorescein angiography (FFA)
and OCT for retinal thickness and volume measurements at
the parafoveal region were done. The HFA revealed bilateral
superior paracentral scotomas, FFA demonstrated RPE loss and
OCT revealed anatomical evidence of loss of ganglion cell layers,
causing marked thinning of the macula and parafoveal region.
Parafoveal retinal thickness and volume measurements may be
early evidence of chloroquine toxicity, and OCT measurements
as a part of chloroquine toxicity screening may be useful in early
detection of chloroquine maculopathy.</p>
      </abstract>
      <kwd-group>
        <kwd>Chloroquine maculopathy</kwd>
        <kwd>optical coherence tomography</kwd>
        <kwd>retinal thickness</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Ocular toxicity associated with antimalarial agents have
been extensively studied since its first description in 1957
by Cambiaggi.<xref ref-type="bibr" rid="ref1">1</xref> Several tools have been used to detect
functional loss for diagnosis including color vision, Amsler
grid, Humphrey field analyzer (HFA) and multifocal
electroretinography.<xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref3">3</xref></p>
    <p>Although the vision loss from chloroquine toxicity has been
attributed to retinal pigment epithelial (RPE) changes and
consequent photoreceptor loss, several animal studies have
suggested that the initial retinal damage occurs in ganglion
cells, and the other retinal layers are affected only later on.<xref ref-type="bibr" rid="ref4">4</xref>
Scanning laser polarimetry has shown that there is a marked
thinning of the nerve fiber layer, possibly due to ganglion cell
damage.<xref ref-type="bibr" rid="ref4">4</xref> Optical coherence tomography (OCT) gives a good
cross-sectional view of the macula and may be a good tool for
the detection of anatomical evidence of chloroquine macular
toxicity.<xref ref-type="bibr" rid="ref5">5</xref> We report the OCT findings in a case of chloroquine
macular toxicity, which, to the best of our knowledge has so
far not been reported.</p>
    <sec sec-type="">
      <title>Case Report</title>
      <p>A 53-year-old lady, of height 152 centimeters and weighing 45
kilograms diagnosed with rheumatoid arthritis was first seen
by us in April 2003 for a pre-chloroquine workup. Her vision
was 20/20 N<sub>6</sub> bilaterally. She was trichromatic (17/17) using
the Ishihara isochromatic charts. Fundus examination, Amsler
grid testing and HFA 10-2 were normal. Chloroquine 250 mg
daily was then started.</p>
      <p>She was seen at six-monthly intervals and advised
Amsler grid self-evaluation between her scheduled eye
examinations.</p>
      <p>In April 2006, the vision in her left eye dropped to 20/30
N<sub>8</sub> with no subjective change in vision. She was trichromatic,
although taking longer to identify the numbers. A clinically
detectable RPE disturbance was noted, more prominent in
her left eye [Figures <xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F2">2</xref>]. Amsler grid evaluation was 
normal, but HFA 10-2 revealed, repeatable superior paracentral defect
in both eyes [<xref ref-type="fig" rid="F3">Figure 3</xref>]. Fundus fluorescein angiography
(FFA) revealed RPE defects in the macular region in both
eyes. A recommendation to the treating internist was made
to replace chloroquine with hydroxychloroquine. At review
four months later, she reported distortion of vision in both
eyes, which was reflected as a small blurred area in the center
of the Amsler grid and vision in both eyes of 20/30 N<sub>8</sub></p>
      <p>Optical coherence tomography (Stratus 4 OCT&#x2122;; Carl Zeiss
Meditec, Dublin, Calif) revealed a marked retinal thinning of
the parafoveal region [<xref ref-type="fig" rid="F4">Figure 4</xref>].</p>
      <p>The internist was informed and hydroxychloroquine was
replaced by methotrexate. Since then, her vision has remained
stable at 20/30 N<sub>8</sub>.</p>
    </sec>
    <sec sec-type="">
      <title>Discussion</title>
      <p>Chloroquine, and more recently, the apparently less toxic
hydroxychloroquine, is used for long periods of time for
treatment of various autoimmune disorders. Cambiaggi
first described the classic RPE changes in 1957<xref ref-type="bibr" rid="ref1">1</xref> and Hobbs
in 1959 established a definite link between long-term use
of chloroquine and subsequent development of retinal
pathology.<xref ref-type="bibr" rid="ref6">6</xref></p>
      <p>Early chloroquine retinopathy though still inadequately
described, is defined as an acquired paracentral scotoma
on threshold visual field testing, with no detectable retinal
findings, while advanced retinopathy has associated parafoveal
RPE atrophy.<xref ref-type="bibr" rid="ref7">7</xref> Chloroquine and its metabolites have been found
in the pigmented ocular structures at concentrations much
greater than in any other tissue in the body, which may explain
its toxic properties in the eye.<xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref8">8</xref> Animal studies have
suggested that ganglion cell damage occurs early with choloroquine.<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref8">8</xref> Human pathological studies are however limited to patients
with advanced maculopathy.<xref ref-type="bibr" rid="ref3">3</xref></p>
      <p>Detection of resultant thinning of the ganglion cell and
nerve fiber layer (NFL) would be useful in demonstrating
the initial stages of toxicity, perhaps at a stage when further
damage can be halted by stopping the drug at this point.
The NFL measurements of the peripapillary region in
patients on antimalarials by scanning polarimetry have
indeed shown a significant thinning of the NFL which was
dose and duration-dependent.<xref ref-type="bibr" rid="ref4">4</xref> However, the ganglion cell
population is the densest in the macular region, and hence,
toxicity of the drug would be greatest at this location. The
fact that the first functional change is a paracentral scotoma,
and the first observable RPE changes are seen in this area
supports this assumption.<xref ref-type="bibr" rid="ref7">7</xref> Thus retinal thickness and volume
measurements in this area may give more accurate and earlier
predictions of chloroquine toxicity, perhaps even before the
scotoma develops. The OCT, with its high resolution provides
measurements of the retinal thickness and volume, both in
the peripappillary area as well as at the macular region. It
also gives information on the status of the retinal pigment
epithelium, clearly revealing RPE defects. In addition, the
limitations of the scanning laser polarimeter with respect
to inaccuracies related to corneal and lens birefringence are
not present.</p>
      <p>A recent study using a research prototype of a high-speed
ultra-high-resolution OCT reported discontinuity or loss
of perifoveal photoreceptor inner segment/outer segment
junctions and thinning of the outer nuclear layer in 15 patients
receiving hydroxychloroquine.<xref ref-type="bibr" rid="ref5">5</xref> This instrument is however not
available as yet for general clinical use.</p>
      <p>In our patient [<xref ref-type="fig" rid="F2">Figure 2</xref>], the fovea (central circle) is of
normal thickness while the perifoveal (inner circle) and
peripheral (outer circle), are thinned mainly temporally and
inferiorly. This is in agreement with the universally accepted
early superior paracentral scotoma, also seen in this patient
[<xref ref-type="fig" rid="F1">Figure 1</xref>].</p>
      <p>Although reports in the older literature on chloroquine
toxicity had suggested that the cumulative dose of chloroquine
was the critical factor for toxicity, current evidence suggests
that cumulative dosage and duration of therapy are relatively
unimportant and that the crucial index is daily dosage
normalized by lean body weight.<xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref9">9</xref> In this patient, the
dose of chloroquine she was on clearly exceeded the recommended
daily dose of 4 mg/kg/day.<xref ref-type="bibr" rid="ref10">10</xref> This is probably why she
developed maculopathy just 36 months after starting the
chloroquine therapy for her rheumatoid arthritis.</p>
      <p>Long-term prospective studies may determine when retinal
thinning starts in patients on antimalarials, and whether
irreversible paracentral field defects could be prevented if
antimalarials are stopped on first detection of thinning.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cambiaggi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Unusual ocular lesions in a case of systemic lupus
erythromatosis</article-title>
          <source>Arch Ophthalmol</source>
          <year>1957</year>
          <volume>57</volume>
          <fpage>451</fpage>
          <lpage>53</lpage>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Easterbrook</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Detection and prevention of maculopathy associated
with antimalarial agents</article-title>
          <source>Int Ophthalmol Clin</source>
          <year>1999</year>
          <volume>39</volume>
          <fpage>49</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="pmid">10343924</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neubauer</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Stiefelmeyer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Berninger</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Arden</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Rudolph</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>The multifocal pattern electroretinogram in chloroquine
retinopathy</article-title>
          <source>Ophthalmic Res</source>
          <year>2004</year>
          <volume>36</volume>
          <fpage>106</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">15017107</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonanomi</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Dantas</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Medeiros</surname>
              <given-names>FA</given-names>
            </name>
          </person-group>
          <article-title>Retinal nerve fibre layer
thickness measurements in patients using chloroquine</article-title>
          <source>Clin Exp Ophthalmol</source>
          <year>2006</year>
          <volume>34</volume>
          <fpage>130</fpage>
          <lpage>6</lpage>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodriguez-Padilla</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Hedges</surname>
              <given-names>TR</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Monson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Srinivasan</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Wojtkowski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Reichel</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High-speed ultra-high-resolution
optical coherence tomography findings in hydroxychloroquine
retinopathy</article-title>
          <source>Arch Ophthalmol</source>
          <year>2007</year>
          <volume>125</volume>
          <fpage>775</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">17562988</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hobbs</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Sorsby</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Freedman</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Retinopathy following
chloroquine therapy</article-title>
          <source>Lancet</source>
          <year>1959</year>
          <volume>2</volume>
          <fpage>478</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">14402143</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Browning</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Hydroxychloroquine and chloroquine retinopathy:
Screening for drug toxicity</article-title>
          <source>Am J Ophthalmol</source>
          <year>2002</year>
          <volume>133</volume>
          <fpage>649</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="pmid">11992862</pub-id>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramsey</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Fine</surname>
              <given-names>BS</given-names>
            </name>
          </person-group>
          <article-title>Chloroquine toxicity in the human eye:
Histopathologic observations by electron microscopy</article-title>
          <source>Am J Ophthalmol</source>
          <year>1972</year>
          <volume>73</volume>
          <fpage>229</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="pmid">4335678</pub-id>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mackenzie</surname>
              <given-names>AH</given-names>
            </name>
          </person-group>
          <article-title>Dose refinements in long-term therapy of
rheumatoid arthritis with antimalarials</article-title>
          <source>Am J Med</source>
          <year>1983</year>
          <volume>75</volume>
          <fpage>40</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">6869410</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marmor</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Carr</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Easterbrook</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Farjo</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Mieler</surname>
              <given-names>WF</given-names>
            </name>
          </person-group>
          <article-title>Recommendations on screening for chloroquine and
hydroxychloroquine retinopathy: A report by the American
Academy of Ophthalmology</article-title>
          <source>Ophthalmology</source>
          <year>2002</year>
          <volume>109</volume>
          <fpage>1377</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">12093666</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Right eye fundus photograph showing clinically detectable
retinal pigment epithelial changes at the macula in a patient on
chloroquine therapy for rheumatoid arthritis</p>
      </caption>
      <alt-text>Figure 1</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-511-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Left eye fundus photograph showing clinically detectable
retinal pigment epithelial changes at the macula of the same patient</p>
      </caption>
      <alt-text>Figure 2</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-511-g002"/>
    </fig>
    <fig id="F3" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Humphrey Field Analyzer 10-2 program showing superior paracentral field defects in both eyes of the patient</p>
      </caption>
      <alt-text>Figure 3</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-511-g003"/>
    </fig>
    <fig id="F4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Retinal thickness and volume measurements at the
parafoveal region of a patient with chloroquine maculopathy</p>
      </caption>
      <alt-text>Figure 4</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-511-g004"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
